Seropin drug 100mg genepharm treatment of schizophrenia (60 tablets)

quetiapine is an aligned anti -psychotic drug. Quetiapine and active metabolites in plasma are Norquetiapine that acts on many types of neurotransmitter receptors.

Quetiapine and Norquetiapine have a work of serotonin receptors (5HT2) in the brain and with Dopamine D1 and D2 receptors. The antagonism on these receptors and the selection with the serotonin receptor (5HT2) is higher than the Dopamine D2 receptor, which is considered to contribute to the clinical anti -psychotic properties and have little risk of side effects on the pulp of quote of Quetiapine. In addition, Norquetiapine has high affinity with norepinephrine transportation (NET). Quetiapine and norquetiapine also have high affinity with histaminergic and α1 - adrenergic receptors, lower affinity with α2 - adrenergic receptors and 5HT1A serotonin receptors. Quetiapine has negligible affinity for the Cholinergic Muscarinic or Benzodiazepine receptors.

Pharmacy impact

Quetiapine is active in the tests of anti -psychotic effects, conditional evasion tests, Quetiapine closed the impact of dopamine agents, on electrical behavioral trials or physiology and increasing the concentration of metabolites of dopamine, a nerve index indicates the level of D2 receptor clutches.

In preclinical trials forecasting the possibility of extracurricular symptoms (EPS), Quetiapine is not like typical anti -psychotic drugs and has no typical characteristics. Quetiapine is not too sensitive to Dopamine D2 receptors when used for long term. Quetiapine can cause the syndrome to keep the weak at doses of Dopamine receptor inhibitors D2.

Quetiapine proves to be selective on the edge of the brain through the reducing inhibition effect of neurons in the middle brain border but does not act on black -patterned neurons after long -term use. Quetiapine can cause a minimum muscle disorder on the cebus monkey sensitive to Haloperidol or have never taken the drug after taking the medication immediately and for a long time.

The results of these tests show that seropin is likely to cause low -level symptoms, the assumption is that it is less likely to cause pagoda symptoms and the ability to cause less dysplasia.

It is unknown to metabolites norquetiapine to contribute to the pharmacological characteristics of the seropin on humans.

pharmacokinetics

quetiapine absorbs well and completely metabolized after drinking. Quetiapine's bioavailability is not significantly affected by food. The drug is associated with plasma protein about 83%. In a stable state, the maximum concentration of metabolites has anorquetiapine activity equal to 35% of quetiapine concentration. Quetiapine and norquetiapine waste time corresponds to about 7 and 12 hours, respectively. The pharmacokinetics of Quetiapine and Norquetiapine are linear when using the approved doses.

The average clearance of Quetiapine in the elderly is about 30-50% lower than the 18-65 years of age.

Quetiapine average clearance in plasma decreased by about 25% in patients with severe renal impairment (CLCR

After taking quetiapine, the original active ingredient accounts for In vitro, CYP3A4 are the main enzyme metabolic quetiapine through cytochrome p450 intermediaries. Norquetiapine is mainly formed and eliminated through CYP3A4.

quetiapine and its metabolites (including Norquetiapine) are weak inhibitors of Cytochrome P450 1A2, 2C9, 2C19, 2D6 and 3A4 In vitro. This inhibitor is only seen at a dose higher than 5 - 50 times the dose of 300 - 800mg/day in humans. The combination of quetiapine with other drugs will not significantly inhibit the metabolism through the cytochrome P450 intermediate of combined drugs. In vivo, quetiapine can cause induction cytochrome p450 enzymes. However, in a specific interactive study in psychotic patients, there is no increase in the activity of cytochrome P450 after using Quetiapine.

Precautions when using

children and young people

Quetiapine is not recommended for use in children and young people under 18 years old, due to no safe data to support use in these age groups. Certain adverse effects appear with high frequency in children and adolescents (increasing appetite, increasing blood prolactin, vomiting, rhinitis, fainting), different impacts in children and adolescents (pagoda syndrome and easily stimulated changes in thyroid function tests) and an unprecedented adverse effect in adults (hypertension).

In the control tests with fake in children and adolescents, Quetiapine is related to the increase in the surgeon syndrome compared to the placebo in patients treated with schizophrenia, bipolar and bipolar depression.

suicide

Depression in bipolar disorder is associated with an increase in the risk of suicide thoughts, self -damage and suicide. This risk still exists until the significant remission appears. Because improvement may not occur in the first weeks of treatment, patients need to be closely monitored until improved. The risk of suicide may increase in the early stages of recovery.

Consider potential risks after stopping the Quetiapine treatment suddenly. Other mental conditions that quetiapine prescribed may also be associated with increased risk of suicide.

Closely monitor patients with a commercial effect of suicide or significant manifestations of suicide intent before starting treatment. The patient's sealed monitoring should be accompanied by drug treatment, especially in early treatment and after changing the dose.

Cardiovascular disease

Use a cautious medication for patients with cardiovascular disease, cerebrovascular disease, or other conditions that cause hypotension. Reduce the dose or adjust the dose slowly if the vertical hypotension occurs, especially in the starting dose period.

convulsions

Caution in patients with a history of convulsions.

Symptoms of foreign tower

If the signs and symptoms of late movement disorders appear, reduce the dose or discontinue treatment with quetiapine should be considered.

malignant syndrome due to sedative

Clinical manifestations: Increasing body temperature, changing mental state, muscle spasm, unstable autonomous nervous system, increasing creatine phosphokinase. Stop using quetiapine and taking appropriate treatment.

Severe neutropenia

Most cases of severe neutropenia (

Risk factors: The previous low leukocyte and medical neutropenia history. Quetiapine should be discontinued in patients with neutrophils

Hyperglycemia

Monitoring patients with diabetes or risk factors for disease can increase blood glucose or seriously cause disease when treated with quetiapine.

lipid

There are reports on triglycerides and cholesterol when treated with quetiapine.

extends the range of qt

extends the QT distance recorded in case of an overdose. Be careful when using quetiapine for cardiovascular patients or family history showing signs of extending the QT range. Be cautious when using quetiapine and drugs that extend about QTC, other sedatives (especially in the elderly, patients have congenital QT syndrome, congenital heart failure, heart hypertrophy, potassium or blood magnesium).

Cowdown syndrome

Symptoms of acute cessation after a sudden stop of high doses of quetiapine: nausea, headache, diarrhea, dizziness, irritation, vomiting, insomnia. Stop the drug slowly within the minimum period of 1-2 weeks.

Elderly patients with mental disorders involved in dementia

Seropin has not been approved for the treatment of mental disorders related to dementia. Use cautious drugs for groups of objects with risk factors.

The ability to drive and operate machinery

Due to the main impact on the central nervous system, Quetiapine may affect the activities that need mental alertness. Therefore, it is necessary to advise patients not to drive or operate the machine until it is clearly identified by their own drugs.

Pregnancy

Quetiapine effectiveness and safety during pregnancy has not been established. In Vivo has no signs of harmful, but the impact may occur on the eyes of the embryo has not been studied. Therefore, seropin should only be used during pregnancy when the benefits are out of risk, the cessation syndrome in infants has been recorded when the mother uses Quetiapine during pregnancy.

Breastfeeding period

is not clear about the level of Quetiapine secretion into breast milk. Therefore, women who are breastfeeding should avoid using seropin.

Drug interaction

Quetiapine mainly affects the central nervous system, cautious when coordinating with drugs that affect other central nervous systems and alcohol.

Cytochrome P450 (CYP3A4) is the main enzyme metabolic quetiapine. Simultaneous use of quetiapine (dose of 25mg) with ketoconazole (CYP3A4 inhibitors), increasing the AUC of Quetiapine 5 - 8 times. Contraindicated using quetiapine simultaneously with CYP3A4 inhibitors. It is not recommended to use grapefruit juice while being treated with quetiapine.

Simultaneous use of quetiapine with carbamazepine, phenytoin significantly increases the quetiapine clearance, reducing quetiapine concentration may affect the effectiveness of seropin treatment. In patients who are using liver enzyme -induced drugs, they should only start the treatment with seropin after the doctor considers the benefits of seropin than stopping the use of liver enzyme drugs. It is important to stop the drug that causes liver enzyme slowly, if necessary, replace it with non -causing liver enzyme (sodium valproate).

pharmacokinetics of sodium valproate and quetiapine does not change when used simultaneously.

Be cautious when coordinating quetiapine with drugs that cause electrolyte imbalance or extending the QT range.